RespireRx Pharmaceuticals Inc.
RSPIOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$657754
P/E Ratio—
52W High$0.0027
52W Low$0.0001
RespireRx Pharmaceuticals Inc. (RSPI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RSPI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.04 | $-0.04 | $-0.22 | $-6.45 | $-7.73 |
| Wtd Avg Shares | 0.11B | 0.09B | 0.03B | 0.00B | 0.00B |
| EBITDA | ($0.00B) | $0.00B | ($0.00B) | $0.00B | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more RespireRx Pharmaceuticals Inc. data
About RespireRx Pharmaceuticals Inc. (RSPI) Income Statement
RespireRx Pharmaceuticals Inc. (RSPI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, RSPI reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
RSPI · 4 questionsRespireRx Pharmaceuticals Inc. (RSPI) reported revenue of $0.00B for 2022, down —% year-over-year.
RSPI revenueRSPI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09